What is the dosage of oral semaglutide?
| Product | Tablet strengths |
|---|---|
| Rybelsus tablets, US label | 3, 7 and 14 mg2 |
| Ozempic tablets, US label | 1.5, 4 and 9 mg2 |
| Wegovy tablets, US label | 1.5, 4, 9 and 25 mg1 |
| Rybelsus, EU product information | 1.5, 4, 9, 25 and 50 mg in one set; 3, 7, 14, 25 and 50 mg in another3 |
The US Wegovy tablet label, for adults with obesity or overweight (for weight reduction, or for cardiovascular risk reduction with established cardiovascular disease), starts at 1.5 mg once daily for 30 days, then steps to 4, 9 and 25 mg1; the US Rybelsus label, for adults with type 2 diabetes, starts at 3 mg once daily, then 7 mg, then 14 mg if more glycemic control is needed.2
Tablet strengths by label
The table is set at the top of the page
The US label says the Rybelsus and Ozempic tablets are not substitutable mg for mg.2 The US label allows a switch between Rybelsus and Ozempic tablets after the initiation phase but not during it.2
Starting dose and step-up on the labels
| Label | First 30 days | Next 30 days | After that |
|---|---|---|---|
| Rybelsus, US | 3 mg | 7 mg | 7 mg, or 14 mg if more glycemic control is needed2 |
| Ozempic tablets, US | 1.5 mg | 4 mg | 4 mg, or 9 mg if more glycemic control is needed2 |
| Wegovy tablets, US | 1.5 mg | 4 mg | 9 mg for days 61 to 90, then 25 mg from day 911 |
The US label gives the Rybelsus and Ozempic schedules for adults with type 2 diabetes and calls the 3 mg and 1.5 mg starting doses not effective for glycemic control.2 The Wegovy label, for adults with obesity or overweight (with established cardiovascular disease for cardiovascular risk reduction, or with at least one weight-related comorbid condition for weight reduction in overweight), titrates every 30 days, says to consider delaying escalation if a dose is not tolerated, and gives 25 mg once daily as the maintenance dose.1 The EU text, for adults with insufficiently controlled type 2 diabetes, gives 1.5 mg once daily for one month, then a 4 mg maintenance dose, with escalation to the next higher dose after at least one month if needed.3 Its maintenance doses are 4 mg, 9 mg, 25 mg and 50 mg.3
What the trials used
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| PIONEER 1 (Aroda, 2019) | Oral semaglutide 3 mg, 7 mg or 14 mg, or placebo, once daily, randomised 1:1:1:14 | 703 adults with type 2 diabetes insufficiently controlled with diet and exercise | 26 weeks |
| OASIS 4 (Wharton, 2025) | Oral semaglutide 25 mg or placebo once daily, randomised 2:156 | 307 adults without diabetes with overweight or obesity | 71 weeks |
| OASIS 1 (Knop, 2023) | Oral semaglutide escalated to 50 mg, or placebo, once per day, randomised 1:17 | 667 adults with overweight or obesity without type 2 diabetes | 68 weeks |
For the 307-adult trial registered as NCT05564117, the registry entry lists once-daily dose increases every 4 weeks to week 12 (3 mg, 7 mg and 14 mg), then 25 mg once daily to week 64.56
How the tablet is taken
The US Rybelsus and Ozempic tablet label says to take one tablet once daily on an empty stomach in the morning with up to 4 ounces of water.2 It asks for at least 30 minutes before food, drinks or other oral medicines.2 The Wegovy label gives the same administration, including the wait of at least 30 minutes before food, drinks or other oral medicines.1 The EU text asks for a fast of at least 8 hours and a sip of water up to 120 mL.3 It also asks for a wait of at least 30 minutes, and says waiting less decreases absorption.3
Storing the tablets
The US Rybelsus and Ozempic tablet label gives 20°C to 25°C, with excursions allowed to 15°C to 30°C, with the tablets kept in the original bottle until use to protect them from moisture.2 The Wegovy medication guide gives room temperature between 68°F to 77°F (20°C to 25°C), in the original closed bottle, in a dry place away from moisture.1 The EU text gives the original blister package, with no special temperature storage conditions.3
Frequently asked questions
How do labels say to switch from weekly injections to tablets?
Does oral semaglutide need mixing, or a syringe?
Searches of DailyMed, the EU product information, ClinicalTrials.gov and PubMed found no label, no human trial and no stability data for oral semaglutide as a liquid, drops or powder.
References
- DailyMed (Novo Nordisk). These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017. 2026. dailymed.nlm.nih.gov
- DailyMed (Novo Nordisk). These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (semaglutide) tablets, for oral use OZEMPIC (semaglutide) tablets, for oral use Initial U.S. Approval. 2026. dailymed.nlm.nih.gov
- EMA. Rybelsus, INN-semaglutide. ema.europa.eu
- PubMed. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. 2019. pubmed.ncbi.nlm.nih.gov
- PubMed. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. 2025. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05564117: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range. 2026. clinicaltrials.gov
- PubMed. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. 2023. pubmed.ncbi.nlm.nih.gov